1-3 of 3
Gilles Tremblay
Close
Sort by
Journal Articles

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

John Mascarenhas, MD, Heidi E. Kosiorek, MS, Lilian Varricchio, PhD, Rupali Bhave, MD, Andrew T. Kuykendall, MD, Rami Komrokji, MD, Aaron T. Gerds, MDMS, Jeanne M. Palmer, MD, Amelia R. Gabler, Lonette Sandy, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Maureen O'Connor-McCourt, PhD, Gilles Tremblay, PhD, Paul I. Nadler, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–8.
https://doi.org/10.1182/blood-2020-140830
Published: 2020
Journal Articles

AVID200, a Potent Trap for TGF-β Ligands Inhibits TGF-β1 Signaling in Human Myelofibrosis

Lilian Varricchio, PhD, John Mascarenhas, MD, Anna Rita Migliaccio, PhD, Maureen O'Connor-McCourt, PhD, Gilles Tremblay, Jean-François Denis, Camelia Iancu-Rubin, PhD, Ronald Hoffman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1791.
https://doi.org/10.1182/blood-2018-99-116474
Published: 2018
Journal Articles

AVID200: A Novel TGF-β Inhibitor for the Treatment of Anemia Associated with Myelodysplastic Syndromes

Michael Thwaites, PhDBSc, James Koropatnick, PhD BSc, MSc, Gilles Tremblay, PhD, Maureen O'Connor-McCourt, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2532.
https://doi.org/10.1182/blood.V130.Suppl_1.2532.2532
Published: 2017